Catalent: $1bn over the past 5 years

As previously reported, Catalent recently acquired Acuccaps​ and Pharmatek​ to “provide additional breadth​” to its portfolio, Elliot Berger, VIP Global Strategy said.

“We believe the industry … has a few challenges bringing enough good products to market fast enough, and doing it at a cost that will yield itself to a value equation acceptable to payers and industry,​” he added.

“Part of the problem is in the drug development process where it takes a long time to get the molecule through the process​,” he added. “We believe that no molecule should die in the process for the lack of formulation options​.”

To overcome these challenges, Berger said there are a large number of proven integrated drug delivery technologies available.

Over the past 5 years, he added that Catalent has spent more than $1bn to increase its capabilities.

“What we’re trying to do is complete that set of technology … to make sure we [are meeting] the needs of the more complicated, sophisticated pipeline,​” he said.

With its recent acquisitions, Catalent has more than 30 sites that supply 70bn doses of more than 7,000 products to more than 1,000 customers.